Ritonavir-Saquinavir Dual Protease Inhibitor Compared to Ritonavir Alone in Human Immunodeficiency Virus-Infected Patients

The objective of this study was to evaluate the antiretroviral efficacy and safety of ritonavir (600 mg twice a day [b.i.d.])-saquinavir (400 mg b.i.d.) compared to ritonavir (600 mg b.i.d.) in patients pretreated and receiving continued treatment with two nucleoside analogs. The study was placebo c...

Полное описание

Библиографические подробности

Опубликовано в::	Antimicrob Agents Chemother
Главные авторы:	Michelet, Christian, Ruffault, Annick, Sébille, Véronique, Arvieux, Cedric, Jaccard, Philippe, Raffi, François, Bazin, Claude, Chapplain, Jean-Marc, Chauvin, Jean-Pierre, Dohin, Elisabeth, Cartier, François, Bellissant, Eric
Формат:	Artigo
Язык:	Inglês
Опубликовано:	American Society for Microbiology (ASM) 2001
Предметы:	Antiviral Agents
Online-ссылка:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90843/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11709314/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.45.12.3393-3402.2001
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!